Skip to main content

Industry insights

Publications

Cost-effectiveness of difelikefalin for the treatment of moderate to severe chronic kidney disease-associated pruritus (CKD-aP) in adult patients receiving in-centre haemodialysis

Cameron Collins, Tom Edmonds, Imogen Taylor, Andrew Mumford, Oliver Darlington, Thilo Schaufler, Marco Soro, Garth Baxter

Estimates on waste of breast cancer related chemotherapy drugs in the NHS (England)

Charlotte Ahmadu, Tom Edmonds, Elise Evers

The Cost-Effectiveness of Immunotherapies for Advanced or Recurrent Endometrial Cancer: A Systematic Review

Charlotte Ahmadu, Sarah Coyle, Oliver Darlington

The Guardian supplement – Rare Disease Q3 2023

Sarah Coyle, Harry Lewis, Andrew Mumford

An evaluation of the design of clinical trials conducted for rheumatoid arthritis, 2009-2022

Oliver Darlington, Myrtle Greenwood, Adelaide Shaw-Maguire, Imogen Taylor

The Cost-Effectiveness of Immunotherapies for Advanced Biliary Tract Carcinoma: A PRISMA Systematic Literature Review

Charlotte Ahmadu, Sarah Coyle, Jonathan Gibson and Tiyi Morris

Listen to our podcast: Initiation

Working with Initiate | What to expect working with our market access and health economics consultancy | Initiation Podcast

Developing PROMs in rare diseases | A conversation with Benson Chen from MitoCAMB | Initiation Podcast

Insights from the 2023 Reimbursement Radar wrap-up | Initiation Podcast

View more in Spotify

Events & conferences

We attend a number of major conferences and would love to meet you at the events listed below:

World Orphan Drug Congress US 2025

22nd – 24th April 2025

ISPOR US 2025

13th – 16th May 2025

Talks & webinars

As market access and HEOR experts, we are regularly asked to talk at industry events. We’d love to see you in our audience at the following events:

Life Science Access Academy

Value Based Healthcare for Life Sciences Made Simple

Monday 17th March 13:00 – 14:00 (GMT)